Helix BioPharma Corp. (TSX:HBP, OTC PINK:HBPCD, FRANKFURT:HBP0), a clinical-stage oncology company, announced on February 24, 2026, that it presented new data on its CEACAM6-directed antibody-drug conjugate (ADC) program at the 16th Annual World ADC London conference in London, United Kingdom. The presentation, titled “Next-Generation ADCs: Unlocking the Potential of CEACAM6-Directed Targeted Therapies,” was delivered by Jonathan Davis, PhD, Director of ADC Discovery at Helix BioPharma, as part of the conference’s Seminar Day program.
Dr. Davis highlighted CEACAM6 as a highly attractive therapeutic target due to its elevated expression across a broad range of epithelial cancers, its association with poor clinical outcomes, and its limited expression in healthy tissues. The presentation included data supporting the tumor-selective binding profile of Helix’s proprietary anti-CEACAM6 VHH, a single-domain antibody fragment derived from camelid antibodies (also known as a “nanobody”). This VHH demonstrated preferential binding to tumor-expressed CEACAM6, supporting the development of next-generation ADCs designed to deliver potent therapeutic payloads directly to cancer cells while minimizing off-target effects. The work builds on the clinical foundation set by Tumor Defense Breaker™, L-DOS47, Helix’s lead CEACAM6-targeted candidate, which has shown favorable safety and encouraging clinical activity in Phase I/II studies in non-small cell lung cancer (NSCLC).
“CEACAM6 represents a compelling and underexploited target with broad potential across multiple hard-to-treat cancers,” said Dr. Davis. “Our proprietary VHH-based targeting approach enables highly selective tumor binding, supporting the development of next-generation ADCs designed to maximize therapeutic impact while minimizing off-target effects. Our presentation generated strong interest and discussion among conference participants, reflecting the growing recognition of CEACAM6 as an important emerging target in oncology.”
A copy of Dr. Davis’ presentation is available on the Company’s website under the “Events and Presentations” page at this link.
World ADC London is a global, annual conference dedicated to the discovery, development, and commercialization of antibody-drug conjugates. Now in its 16th year, it is one of the leading global conferences for ADC research and development, bringing together more than 700 industry stakeholders from over 240 companies. More information about the conference can be found at worldadc-europe.com.
Helix BioPharma is an oncology company focused on bringing near-term solutions for hard-to-treat cancers. Its pipeline includes L-DOS47, a clinical-stage antibody-enzyme conjugate designed to prime CEACAM6-expressing tumors for increased sensitivity to therapy. The company also advances two pre-IND candidates: LEUMUNA™, an oral immune checkpoint modulator, and GEMCEDA™, a first-in-class oral gemcitabine prodrug. Helix is listed on the TSX (HBP), OTC PINK (HBPCD), and FWB (HBP0). For more information, visit helixbiopharma.com.
